Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.79 |
| ▸ | HTR7 | P34969 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HTR5A | P47898 | 1/20 | 0.56 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440302 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL31670342 | 0.99 | HSD17B10 (0.97) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| Formic Acid SCHEMBL31031810 | 0.93 | HSD17B10 (0.87) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL2970063 | 0.90 | HSD17B10 (0.81) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL968283 | 0.88 | HSD17B10 (0.79) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL18346074 | 0.87 | HSD17B10 (0.77) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL30741605 | 0.86 | HSD17B10 (0.76) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL29171344 | 0.86 | HSD17B10 (0.76) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL30741594 | 0.86 | HSD17B10 (0.76) | HSD17B10CYP1A2CYP2D6ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL30889372 | 0.85 | HSD17B10 (0.74) | HSD17B10CYP1A2CYP2D6ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | SINTALICA S R L (IT) | 2026-05-21 | — | — | US | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4638419-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-10-29 | — | — | EP | claimed |
| US-20250281399-A1 | A MUCOADHESIVE FILM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT AND USES THEREOF | SHORT WAVE PHARMA INC. (CA) | 2025-09-11 | — | — | US | claimed |
| EP-4601665-A1 | COMPOSITION COMPRISING TRYPTAMINES AND MAOIS COMPOUNDS SELECTED FROM ?-CARBOLINE INHIBITORS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4601627-A1 | COMPOSITION COMPRISING NOT PHOSPHORYLATED TRYPTAMINE, ANTIOXIDANTS, AND SUPPLEMENTS, AND PHARMACEUTICAL USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4601655-A1 | DELIVERY SYSTEM FOR THE CONTROLLED RELEASE OF PSYCHEDELIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Sintalica S.r.l. (IT) | 2025-08-20 | — | — | EP | claimed |
| EP-4583856-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | Native Code Bio, LLC (US) | 2025-07-16 | — | — | EP | claimed |
| EP-4518855-A1 | A MUCOADHESIVE FILM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT AND USES THEREOF | Short Wave Pharma Inc. (CA) | 2025-03-12 | — | — | EP | claimed |
| WO-2024134619-A1 | NON-HALLUCINOGENIC TRYPTAMINE COMPOUNDS, PREPARATION, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SINTALICA S.R.L. (IT) | 2024-06-27 | — | — | WO | claimed |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-10-09 | — | — | US | claimed |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-04-20 | — | — | US | claimed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | claimed |
| US-7361681-B2 | Method of treating amytrophic lateral sclerosis using melatonin | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2008-04-22 | — | — | US | claimed |
| US-20060292202-A1 | Drug delivery device | BAUSCH & LOMB INCORPORATED | 2006-12-28 | — | — | US | claimed |
| US-20040192745-A1 | Method of treating amytrophic lateral sclerosis using melatonin | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2004-09-30 | — | — | US | claimed |
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | claimed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | claimed |
| EP-0891187-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-01-20 | — | — | EP | claimed |
| WO-1997037658-A1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 1997-10-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281399-A1 | A MUCOADHESIVE FILM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT AND USES THEREOF | MUC1, CFTR, LIPA | HSD17B10 2597/4885CYP1A2 2053/4885CYP2D6 3149/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | HSD17B10 2048/4885CYP1A2 808/4885CYP2D6 555/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | HSD17B10 1570/4885CYP1A2 1194/4885CYP2D6 2218/4885 |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | INMT, HNMT, CPT1A | HSD17B10 1570/4885CYP1A2 1194/4885CYP2D6 2218/4885 |
| US-20260137652-A1 | Composition Comprising Non-Phosphorylated Tryptamine | HTR2B, BDNF, HTR3B | HSD17B10 2587/4885CYP1A2 3971/4885CYP2D6 3991/4885 |
| US-20170105975-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | HSD17B10 1467/4885CYP1A2 1507/4885CYP2D6 2503/4885 |
| US-20060292202-A1 | Drug delivery device | ALDH1A2, ADRB2, ADRA2B | HSD17B10 967/4885CYP1A2 1391/4885CYP2D6 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.